Board of Directors
News & Media
Systemic Lupus Erythematosus
A clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus.
Hear CMO Dr Mitchell Glass discuss the results of Invion's successful P2 clinical trial in smoking cessation.
Invion has three drug assets in development across four development programs. Two phase II clinical trials are currently underway with the 136 patient smoking cessation study due to report in Q3 2015. Read more
in the latest corporate presentation
R&D tax rebate of $2.4m boosts cash reserves settlement of loan with Metamor Capital Partners
EVP R&D Dr Mitchell Glass discuss with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation
Invion successfully completes phase 2 study of INV102 (nadolol) to aid smoking cessation
Invion Limited – Targeting Inflammation